X

Drug Profile

Anti-CD8 monoclonal antibody

Alternative Names: Anti-CD8; Anti-Leu-2; Anti-Ly-2.1

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Becton, Dickinson and Company
Class Antiretrovirals; Monoclonal antibodies
Mechanism of Action CD8 antigen inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Graft-versus-host disease; Transplant rejection

Most Recent Events

19 Oct 1998 A preclinical study has been added to the pharmacodynamics section
04 Apr 1996 A preclinical study has been added to the pharmacodynamics section
15 Jan 1995 Investigation in Graft-versus-host disease in USA (Unknown route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com